Curative effect of sequential chemotherapy embolization of hepatic arterial infusion of oxaliplatin S-1 combined with hepatic artery on metastatic liver cancer and its influence on survival rate of transfer

Abstract

Objective To investigate the effect of sequential chemotherapy embolization of hepatic arterial infusion of oxaliplatin S-1 combined with hepatic artery on metastatic liver cancer. Methods Sixty-two patients with metastatic liver cancer were selected. According to the different treatment options, they were divided into study group (n=31) and control group (n=31). The control group was treated with hepatic artery chemoembolization (TACE) treatment, the study group was treated with TACE and S-1. The clinical efficacy and the incidence of complications of the two groups were recorded; the liver function index [total bilirubin (TBiL), alanine transfer enzyme (ALT)] and tumor marker alphafetoprotein (AFP) level change between the two groups before and after treatment were compared, the Child-Pugh score changes before and Chapter 3, 6, 12 months after treatment between the two groups and survival rates at different follow-up time (3, 6 and 12 months) between the two groups were compared. Results The efficiency of the study group (45.17%) was significantly higher than that of the control group (19.35%), the difference was significant (P 0.05). Before treatment, TBiL, ALT, AFP levels had no significant difference between the two groups (P>0.05); after treatment, the study group was better than the control group, the differences were significant (P 0.05); The study group was better than the control group after 6, 12 months, the differences were significant (P 0.05), the survival rate of study group 12 months after treatment was significantly higher than that of control group, the difference was significant (P 0.05). Conclusions Sequential chemotherapy embolization of hepatic arterial infusion of oxaliplatin S-1 combined with hepatic artery has good curative effect on metastatic liver cancer, it can effectively improve the clinical efficacy, improve the liver function, improve the long-term survival rate, and does not increase the incidence of complications. Key words: S-1; Transcatheter arterial chemoembolization; Hepatic arterial infusion; Oxaliplatin; Metastatic liver cancer